EANS-Adhoc: AGENNIX AG Reports Notice of Loss Pursuant to § 92 par. 1 AktG

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

other
26.03.2013

Company also Postpones Reporting of Fiscal Year 2012 Financial
Results and Provides Updated Cash Reach Guidance

Planegg/Munich (Germany) and Princeton, NJ, March 26, 2013 - The
Management Board of Agennix AG (Frankfurt Stock Exchange: AGX) with
the concurrence of the Supervisory Board, today provides notification
of a cumulative loss of more than half of the nominal share capital
of the Company. This loss is mainly attributable to the full
impairment of the intellectual property related to talactoferrin. The
Management Board is actively discussing with the Supervisory Board
different options for the Company.

Pursuant to Sec. 92 par. 1 German Stock Corporation Act
("Aktiengesetz"), a loss amounting to half of the nominal share
capital triggers the statutory obligation to summon a shareholders'
meeting. Agennix will announce the date of such meeting and provide
an invitation to the meeting in the near future. In this meeting, the
Management Board will report on the loss of more than half of the
nominal share capital and discuss the situation of the Company.

Agennix also announces that it will postpone the filing of its fiscal
year 2012 financial results, previously scheduled to be published on
March 28, 2013. The Company will provide an updated reporting date
as soon as possible.

Furthermore, Agennix today provided an update on projected cash
reach, indicating that the Company currently expects to have
sufficient cash to fund ongoing operations into June 2013. This is
an update from earlier guidance indicating that the Company expected
to be able to fund operations only into the first quarter of this
year.

END OF AD HOC ANNOUNCEMENT

Agennix AG is a publicly listed biopharmaceutical company that seeks
to develop novel therapies that have the potential to substantially
lengthen and improve the lives of critically ill patients in areas of
major unmet medical need. The Company's clinical development programs
include oral talactoferrin alfa; a topical gel form of talactoferrin
and RGB-286638, a multi-targeted kinase inhibitor. Agennix's
registered seat is in Heidelberg, Germany. The Company's site of
operation is in Princeton, New Jersey. For additional information,
please visit the Agennix website at www.agennix.com.

This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of
Agennix AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from those expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to
place undue reliance on the forward-looking statements contained in
this ad hoc announcement. There can be no guarantee that the Company
will have or be able to obtain additional financial resources or that
it will be successful in pursuing a strategic transaction.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

Agennix® is a trademark of Agennix AG.

Further inquiry note:
Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 90 40 5 464 or +1 609 524 5884
ir@agennix.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 90 405 464
FAX: +49 89 90 40 5-811
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
regulated dealing/prime standard: Frankfurt
language: English